A focused research collaboration with Nevezyne — applying EnsaliX-designed patterned lipid nanoparticles to prove out formulation and delivery performance, milestone by milestone.
A vaccine-technology company developing next-generation vaccines.
A structured, milestone-driven co-development program — not a one-off service.
Active program advancing through joint, data-gated milestones.
Next-generation vaccines promise broader, more durable protection — but conventional lipid nanoparticle delivery ties them to demanding cold-chain logistics and ionizable-lipid formulations that constrain where, and to whom, a vaccine can realistically be delivered.
Nevezyne needed a delivery system that could carry its vaccine construct with greater stability and a cleaner safety profile — preserving performance while easing the formulation and distribution burden that limits real-world reach.
We proposed a focused collaboration: apply EnsaliX-designed patterned LNPs (pLNPs) to Nevezyne's vaccine construct and prove out formulation and delivery performance together — structured, milestone-driven, and shared at every gate.
EnsaliX designs a pLNP specifically for Nevezyne's construct — not a generic formulation retrofitted to fit.
Performance is measured against agreed delivery and stability endpoints — evidence over assertion.
Structured milestones and joint review keep both teams aligned on the same data and the same goal.
AI-designed patterned lipid nanoparticle tailored to the vaccine construct.
The vaccine payload is formulated into the designed pLNP system.
Stability, immunogenicity, and delivery assessed in agreed models.
Both sides review the same data at each milestone gate.
Put NanoPalm's pLNP platform to the test on your target — a focused, milestone-driven pilot to prove delivery performance on your construct.